About Delcath
Delcath Systems and its proprietary targeted drug delivery system are at the forefront of the regional treatment of cancer. The Company's technology, known as Percutaneous Hepatic Perfusion (PHP), allows physicians to deliver significantly higher doses of anti-cancer drugs to the site of disease without exposing the patient's entire body to those same potent levels of drug. Initial clinical results from studies treating cancer in the liver confirm that delivering more drug to the tumor site, and less to the other regions of the body, enhances tumor shrinkage with improved quality of life over systemic cancer therapies. PHP is currently undergoing testing in Phase III and Phase II clinical trials for a variety of cancers of the liver.
 |
 |
 |
April 22 Quarterly Update
Conference Call
(right click, then select "save target as..." to download
the file - 3.84MB)
Recently reported story by Associated Press
Dr. H. Richard Alexander discusses the Delcath PHP System™
New Jersey reporter writes about observing the first PHP procedure at Morristown Memorial Hospital
Delcath PHP on ABC World News Tonight (Video) (Story)
Delcath Systems Granted
Orphan-Drug Designations for Cutaneous and Ocular
Melanoma